Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220013/S028

TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDM

ABBOTT MEDICAL · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONP220013/S028

What did the FDA approve?

FDA posted a Panel Track supplement for the TactiFlex Duo Ablation Catheter, Sensor Enabled, listing the reason as change to design, components, specifications, or material. The posted statement repeats the device indication for cardiac electrophysiological mapping and ablation in drug refractory recurrent symptomatic paroxysmal atrial fibrillation and concomitant atrial flutter, when used with a compatible radiofrequency or pulsed field generator and three-dimensional mapping system.

The record does not state which design, component, specification, or material was changed. It also does not state whether the supplement altered the indication or whether the posted statement reflects the original or revised labeling. The supplement is tied to PMA P220013, but the database fields do not describe the relationship between this supplement and the original approval beyond the identifier.

FDA approval order statement

The TactiFlex Duo Ablation Catheter, Sensor Enabled is indicated for use in The TactiFlex Duo Ablation Catheter, Sensor Enabled is indicated for use in cardiac electrophysiological mapping and ablation for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation and concomitant atrial flutter, when used in conjunction with a compatible radiofrequency (RF) or pulsed field (PF) generator and three-dimensional mapping system.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Cardiovascular
Decision date
Sep 4, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P220013/S028
Regulatory pathway
PMA supplement
Product code
OAE
Decision code
APPR
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.

Product code
OAE
FDA device class
3

For the original device and its historical approval scope, see PMA P220013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220013 · Original PMA

    TactiFlex Ablation Catheter, Sensor Enabled, TactiSys Quartz Equipment, TactiSys Quartz, TactiFlex Radiofrequency C

  2. P220013/S028 received

    Application receipt date recorded by FDA.

  3. P220013/S028 · FDA decision

    Panel Track

  4. P220013/S034 · Related supplement

    TactiFlex Ablation Catheter, Sensor Enabled

Timeline entries are records held by MedtechLedger for P220013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220013

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalMay 18, 2023FDA
ABBOTT MEDICALPMA supplementSep 22, 2026FDA

Explore the linked device profile

Other records with product code OAE

Product / regulatory recordCompanyPathwayDecision dateSource
STOP Persistent AFP100010/S154
Medtronic Cryocath, LPPMA supplementSep 25, 2026FDA
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
QDOT MICRO SystemP210027/S018
Biosense Webster, Inc.PMA supplementSep 10, 2026FDA
Biosense Webster, Inc.PMA approvalNov 23, 2022FDA
Medtronic Cryocath, LPPMA approvalDec 17, 2010FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
5050 Nathan Ln. N., Plymouth, MN, 55442

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records